A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
A phase 1/2 trial of CHM-2101 CAR-T cells in neuroendocrine tumours, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Chimeric Therapeutics, now recruiting.
Overview
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy is a phase 1/2 interventional study registered as NCT06055439 by Chimeric Therapeutics, with 135 participants planned, started 2024-05-15 and due to reach its primary completion in 2026-05. Interventions recorded: CHM-2101 CAR-T cells.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- Trial64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.